{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Capsule%2FTablet%29&page=2", "query": { "intervention": "Placebo (Capsule/Tablet)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 678, "total_pages": 68, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Capsule%2FTablet%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28Capsule%2FTablet%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-01T10:33:15.291Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01074008", "title": "A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C", "HCV", "Chronic Hepatitis C Infection", "Hepatitis C Genotype 1" ], "interventions": [ { "name": "ABT-450", "type": "DRUG" }, { "name": "ABT-072", "type": "DRUG" }, { "name": "ABT-333", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Peginterferon alpha-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 74, "start_date": "2010-03", "completion_date": "2012-01", "has_results": true, "last_update_posted_date": "2015-01-08", "last_synced_at": "2026-10-01T10:33:15.291Z", "location_count": 25, "location_summary": "Phoenix, Arizona • Anaheim, California • La Jolla, California + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01074008" }, { "nct_id": "NCT01490697", "title": "Developing Memory Reconsolidation Blockers as Novel Posttraumatic Stress Disorder (PTSD) Treatments", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Post-traumatic Stress Disorder" ], "interventions": [ { "name": "Mifepristone", "type": "DRUG" }, { "name": "d-Cycloserine", "type": "DRUG" }, { "name": "Placebo-matching Mifepristone", "type": "DRUG" }, { "name": "Placebo-matching d-Cycloserine (DCS)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Roger K. Pitman, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2009-03", "completion_date": "2015-09", "has_results": true, "last_update_posted_date": "2017-06-29", "last_synced_at": "2026-10-01T10:33:15.291Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Dallas, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01490697" }, { "nct_id": "NCT01871285", "title": "Evaluation of the Tolerability of Switching Subjects on Chronic ATC Opioid Therapy to Buprenorphine HCl Buccal Film", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pain" ], "interventions": [ { "name": "Buprenorphine", "type": "DRUG" }, { "name": "Placebo film", "type": "DRUG" }, { "name": "Oxycodone", "type": "DRUG" }, { "name": "Morphine sulfate", "type": "DRUG" }, { "name": "Placebo capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioDelivery Sciences International", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 39, "start_date": "2013-06", "completion_date": "2014-07", "has_results": true, "last_update_posted_date": "2017-02-27", "last_synced_at": "2026-10-01T10:33:15.291Z", "location_count": 3, "location_summary": "Overland Park, Kansas • Philadelphia, Pennsylvania • Salt Lake City, Utah", "locations": [ { "city": "Overland Park", "state": "Kansas" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01871285" }, { "nct_id": "NCT00481325", "title": "Study of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Generalized Anxiety Disorder" ], "interventions": [ { "name": "pexacerfont", "type": "DRUG" }, { "name": "escitalopram", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "18 Years to 65 Years · Female only" }, "enrollment_count": 260, "start_date": "2007-07", "completion_date": "2008-03", "has_results": false, "last_update_posted_date": "2015-10-12", "last_synced_at": "2026-10-01T10:33:15.291Z", "location_count": 51, "location_summary": "Mesa, Arizona • Burbank, California • Costa Mesa, California + 42 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00481325" }, { "nct_id": "NCT00892437", "title": "Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "COBI", "type": "DRUG" }, { "name": "RTV", "type": "DRUG" }, { "name": "ATV", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" }, { "name": "COBI placebo", "type": "DRUG" }, { "name": "RTV placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2009-05", "completion_date": "2015-01", "has_results": true, "last_update_posted_date": "2016-02-15", "last_synced_at": "2026-10-01T10:33:15.291Z", "location_count": 31, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 23 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00892437" }, { "nct_id": "NCT00953745", "title": "Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Major Depressive Disorder" ], "interventions": [ { "name": "Escitalopram", "type": "DRUG" }, { "name": "Aripiprazole", "type": "DRUG" }, { "name": "Placebo Capsule", "type": "DRUG" }, { "name": "Placebo Tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 43, "start_date": "2009-05", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2018-04-19", "last_synced_at": "2026-10-01T10:33:15.291Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00953745" }, { "nct_id": "NCT02008773", "title": "A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Valacyclovir HCI 500 mg tablets", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 170, "start_date": "2014-03-26", "completion_date": "2017-06-20", "has_results": true, "last_update_posted_date": "2019-01-30", "last_synced_at": "2026-10-01T10:33:15.291Z", "location_count": 13, "location_summary": "Bellflower, California • Los Angeles, California • Riverside, California + 9 more", "locations": [ { "city": "Bellflower", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Santa Ana", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02008773" }, { "nct_id": "NCT07792616", "title": "Electrical Neuromodulation for Modifying Spinal Network Involved in Spasticity", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Spinal Cord Injuries (Complete and Incomplete)", "Spinal Cord Injury", "Spinal Cord Injury Cervical", "Spinal Cord Injury Thoracic", "Spinal Cord Injuries", "Spasticity", "Spasm", "Muscle Spasticity", "Muscle Hypertonia", "Muscle Spasm" ], "interventions": [ { "name": "Transcutaneous spinal stimulation at 30 Hz", "type": "OTHER" }, { "name": "Transcutaneous spinal stimulation at 75 Hz", "type": "OTHER" }, { "name": "Tizanidine", "type": "DRUG" }, { "name": "Baclofen", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "University of Mississippi Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2022-07-13", "completion_date": "2027-07-14", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-01T10:33:15.291Z", "location_count": 2, "location_summary": "Jackson, Mississippi", "locations": [ { "city": "Jackson", "state": "Mississippi" }, { "city": "Jackson", "state": "Mississippi" } ], "official_url": "https://clinicaltrials.gov/study/NCT07792616" }, { "nct_id": "NCT03680976", "title": "Anti-Inflammatory Lipid Mediators in Asthma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "CXA-10", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sally E. Wenzel MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 0, "start_date": null, "completion_date": "2021-04", "has_results": false, "last_update_posted_date": "2018-09-21", "last_synced_at": "2026-10-01T10:33:15.291Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03680976" }, { "nct_id": "NCT01958021", "title": "Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced, Metastatic Breast Cancer" ], "interventions": [ { "name": "Ribociclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "FEMALE", "summary": "18 Years to 100 Years · Female only" }, "enrollment_count": 668, "start_date": "2013-12-17", "completion_date": "2023-03-16", "has_results": true, "last_update_posted_date": "2025-03-07", "last_synced_at": "2026-10-01T10:33:15.291Z", "location_count": 73, "location_summary": "Chandler, Arizona • Sedona, Arizona • Fayetteville, Arkansas + 62 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Sedona", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Berkeley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01958021" } ] }